Taken together, these results indicate that RO‐BIR2 and TRAIL can act synergistically to decrease the proliferation of AML cells regardless of their pre‐existing susceptibility to RO‐BIR2. The gene discussed is TNFSF10; the disease is acute myeloid leukemia.